前列腺癌中度大分割全盆腔放疗急性副作用的患者报告与医生报告一致性前瞻性评估
本研究前瞻性分析176例全盆腔放疗(WPRT)和62例前列腺仅放疗(PRT)患者在中度大分割放疗后2年内泌尿生殖(GU)和胃肠道(GI)不良事件的患者报告结局(PRO)与医生报告结局(CRO)的一致性。WPRT组治疗期间GI评分高于PRT组,但12个月时两组水平相当;复合PRO评分对RTOG G1+事件具有中至良好判别能力。
要点
- WPRT组治疗期间GI的PRO和CRO评分均高于PRT组,但12个月时两组水平相当。
- 复合PRO评分对RTOG G1+事件具有中至良好判别能力(GI AUC 0.65-0.74,GU AUC 0.73-0.82)。
- 常规整合PRO可能有助于早期识别不良事件和个体化临床决策。
核心结论
- WPRT与急性GI不良反应增加相关,但在一年内恢复至PRT水平。
- PRO对RTOG G1+事件具有临床相关的判别价值。
研究设计与样本
- 前瞻性研究,纳入176例WPRT和62例PRT患者,处方剂量为20×3 Gy至PTV,淋巴结受累者区域淋巴结46 Gy。
- 患者通过电子PRO工具报告GU和GI不良事件,同时医生使用RTOG标准分级,随访至放疗后2年。
主要发现
- 治疗期间WPRT组GI的PRO评分均值2.80 vs PRT组2.48(p=0.010),CRO评分均值1.15 vs 0.89(p=0.014)。
- 两组GI评分在12个月时达到相等水平。
- 复合PRO评分判别RTOG G1+事件的AUC:GI 0.65-0.74,GU 0.73-0.82(从急性期至24个月)。
临床怎么用
- 常规整合PRO可能促进更早识别不良事件、分配临床资源和个体化临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcomes of whole-pelvic radiotherapy (WPRT) in the era of moderately hypofractionated radiotherapy for prostate cancer remain sparsely reported. Previous studies indicate a high discrepancy between patient-reported outcomes (PROs) and clinician-reported outcomes (CROs) assessing the same endpoint. This study analyzed the concordance between PROs and CROs for WPRT and prostate-only radiotherapy (PRT) patients. METHODS: Patients received a prescribed dose of 20 × 3 Gy to the planning target volume (PTV) and, in cases of lymph node involvement, 46 Gy to the regional lymph nodes. 176 WPRT and 62 PRT patients reported genitourinary (GU) and gastrointestinal (GI) adverse events through an electronic patient-reported outcome measures tool. Simultaneously, clinicians graded side effects using Radiation Therapy Oncology Group (RTOG) criteria for up to two years post-radiotherapy. Composite GU and GI PRO scores, derived by averaging endpoints, were evaluated for their ability to discriminate RTOG G1+ events via receiver operating characteristic curve analysis. RESULTS: During treatment, WPRT patients exhibited elevated GI scores compared to PRT patients via PROs (mean: 2.80 vs. 2.48, p=0.010) and CROs (mean: 1.15 vs. 0.89, p=0.014), though levels equalized by 12 months. Composite PRO scores demonstrated moderate-to-good discriminatory performance for elevated CRO levels (areas under the curves: GI 0.65-0.74; GU 0.73-0.82) from the acute phase through 24 months. CONCLUSION: WPRT was associated with increased acute GI adverse effects but showed recovery to PRT levels within one year. Results demonstrated that PROs yield clinically relevant discriminatory value. Routine integration of PROs may facilitates earlier adverse event identification, allocation of clinical resources, and individualized clinical decision-making.
引用
- Andexlinger L, Knäusl B, Renner A, et al. Prospective evaluation of acute side effects profiles in moderately hypofractionated whole-pelvic radiotherapy for prostate cancer. Clin Transl Radiat Oncol. 2026. PMID: 42051249. doi:10.1016/j.ctro.2026.101169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。